| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | Director | Common Stock | 150,000 | $84,120 | $0.5608 | 13 Dec 2021 | Direct |
| Aeglea BioTherapeutics, Inc. | Director | Director Stock Option (right to buy) | 43,000 | 07 Jun 2022 | Direct | ||
| Surface Oncology, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 24,000 | 08 Jun 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000120919122036150-shanafelt-armen-2022-06-08 | Surface Oncology, Inc. | 08 Jun 2022 | 1 | $0 | 4 | Director, 10%+ Owner | 10 Jun 2022, 20:00 |
| SYRE | Aeglea BioTherapeutics, Inc. | 07 Jun 2022 | 1 | $0 | 4 | Director | 09 Jun 2022, 21:22 |
| SYRE | Aeglea BioTherapeutics, Inc. | 09 Dec 2021 | 3 | +$549,692 | 4 | Director | 13 Dec 2021, 19:41 |
| /report/000120919121039460-shanafelt-armen-2021-06-08 | Surface Oncology, Inc. | 08 Jun 2021 | 1 | $0 | 4 | Director, 10%+ Owner | 10 Jun 2021, 16:30 |
| SYRE | Aeglea BioTherapeutics, Inc. | 08 Jun 2021 | 1 | $0 | 4 | Director | 09 Jun 2021, 17:27 |